ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males

References

• Araujo A B, Esche G R, Kupelian V, O'donnell A B, Travison T G, Williams R E, Clark R V, McKinlay J B. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007; 92: 4241–4247
   PubMed Web of Science ®Google Scholar
• Gray A, Feldman H A, McKinlay J B, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991; 73: 1016–1025
   PubMed Web of Science ®Google Scholar
• Harman S M, Metter E J, Tobin J D, Pearson J, Blackman M R. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724–731
   PubMed Web of Science ®Google Scholar
• Wu F C, Tajar A, Pye S R, Silman A J, Finn J D, O'Neill T W, Bartfai G, Casanueva F, Forti G, Giwercman A, Huhtaniemi I T, Kula K, Punab M, Boonen S, Vanderschueren D. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors. J Clin Endocrinol Metab 2008; 93: 2737–2745
   PubMed Web of Science ®Google Scholar
• Liverman C T, Blazer D G. Testosterone and Aging: Clinical Research Directions. National Academies Press, Washington, DC 2004
   Google Scholar
• Isidori A M, Giannetta E, Gianfrilli D, Greco E A, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lenzi A. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf) 2005; 63: 381–394
   PubMed Web of Science ®Google Scholar
• Isidori A M, Giannetta E, Greco E A, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005; 63: 280–293
   PubMed Web of Science ®Google Scholar
• Amory J K, Watts N B, Easley K A, Sutton P R, Anawalt B D, Matsumoto A M, Bremner W J, Tenover J L. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89: 503–510
   PubMed Web of Science ®Google Scholar
• Page S T, Amory J K, Bowman F D, Anawalt B D, Matsumoto A M, Bremner W J, Tenover J L. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab 2005; 90: 1502–1510
   PubMed Web of Science ®Google Scholar
• Snyder P J, Peachey H, Hannoush P, Berlin J A, Loh L, Lenrow D A, Holmes J H, Dlewati A, Santanna J, Rosen C J, Strom B L. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 2647–2653
   PubMed Web of Science ®Google Scholar
• Snyder P J, Peachey H, Hannoush P, Berlin J A, Loh L, Holmes J H, Dlewati A, Staley J, Santanna J, Kapoor S C, Attie M F, Haddad J G, Jr, Strom B L. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 1966–1972
   PubMed Web of Science ®Google Scholar
• Bhasin S, Cunningham G R, Hayes F J, Matsumoto A M, Snyder P J, Swerdloff R S, Montori V M. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91: 1995–2010
   PubMed Web of Science ®Google Scholar
• The Practice Committee of the American Society for Reproductive Medicine. Treatment of androgen deficiency in the aging male. Fertil Steril 2004; 81: 1437–1440
   PubMed Web of Science ®Google Scholar
• AACE Hypogonadism Task Force. American Association of Clinical Endocrinologist Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hypogonadism in Adult Male Patients – Update 2002, http://www.aace.com/pub/pdf/guidelines/hypogonadism.pdf; 2002
   Google Scholar
• Morales A, Lunenfeld B. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male. Aging Male 2002; 5: 74–86
   PubMedGoogle Scholar
• Nieschlag E, Swerdloff R, Behre H M, Gooren L J, Kaufman J M, Legros J J, Lunenfeld B, Morley J E, Schulman C, Wang C, Weidner W, Wu F C. Investigation, treatment and monitoring of late-onset hypogonadism in Males. ISA, ISSAM, and EAU recommendations. Eur Urol 2005; 48: 1–4
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Swerdloff R, Behre H M, Gooren L J, Kaufman J M, Legros J J, Lunenfeld B, Morley J E, Schulman C, Wang C, Weidner W, Wu F C. Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2005; 8: 56–58
   PubMedGoogle Scholar
• Nieschlag E, Swerdloff R, Behre H M, Gooren L J, Kaufman J M, Legros J J, Lunenfeld B, Morley J E, Schulman C, Wang C, Weidner W, Wu F C. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl 2005; 28: 125–127
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Swerdloff R, Behre H M, Gooren L J, Kaufman J M, Legros J J, Lunenfeld B, Morley J E, Schulman C, Wang C, Weidner W, Wu F C. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU Recommendations. J Androl 2006; 27: 135–137
   PubMed Web of Science ®Google Scholar
• Morales A, Schulman C C, Tostain J, Wu C W. Testosterone Deficiency Syndrome (TDS) needs to be named appropriately – the importance of accurate terminology. Eur Urol 2006; 50: 407–409
   PubMed Web of Science ®Google Scholar
• Schiavi R C, Schreiner-Engel P, White D, Mandeli J. The relationship between pituitary-gonadal function and sexual behavior in healthy aging men. Psychosom Med 1991; 53: 363–374
   PubMed Web of Science ®Google Scholar
• Travison T G, Morley J E, Araujo A B, O'donnell A B, McKinlay J B. The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab 2006; 91: 2509–2513
   PubMed Web of Science ®Google Scholar
• Kelleher S, Conway A J, Handelsman D J. Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004; 89: 3813–3817
   PubMed Web of Science ®Google Scholar
• Morales A, Spevack M, Emerson L, Kuzmarov I, Casey R, Black A, Tremblay R. Adding to the controversy: pitfalls in the diagnosis of testosterone deficiency syndromes with questionnaires and biochemistry. Aging Male 2007; 10: 57–65
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006; 91: 4335–4343
   PubMed Web of Science ®Google Scholar
• Heinemann L A, Saad F, Heinemann K, Thai D M. Can results of the Aging Males’ Symptoms (AMS) scale predict those of screening scales for androgen deficiency. Aging Male 2004; 7: 211–218
   PubMedGoogle Scholar
• Moore C, Huebler D, Zimmermann T, Heinemann L A, Saad F, Thai D M. The Aging Males’ Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004; 46: 80–87
   PubMed Web of Science ®Google Scholar
• Morley J E, Charlton E, Patrick P, Kaiser F E, Cadeau P, McCready D, Perry HM I II. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239–1242
   PubMed Web of Science ®Google Scholar
• Tancredi A, Reginster J Y, Schleich F, Pire G, Maassen P, Luyckx F, Legros J J. Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers. Eur J Endocrinol 2004; 151: 355–360
   PubMed Web of Science ®Google Scholar
• Beutel M E, Wiltink J, Hauck E W, Auch D, Behre H M, Brahler E, Weidner W. Correlations between hormones, physical, and affective parameters in aging urologic outpatients. Eur Urol 2005; 47: 749–755
   PubMed Web of Science ®Google Scholar
• Diver M J, Imtiaz K E, Ahmad A M, Vora J P, Fraser W D. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol (Oxf) 2003; 58: 710–717
   PubMed Web of Science ®Google Scholar
• Citron J T, Ettinger B, Rubinoff H, Ettinger V M, Minkoff J, Hom F, Kan P, Alloo R. Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism. J Urol 1996; 155: 529–533
   PubMed Web of Science ®Google Scholar
• Bunch T J, Abraham D, Wang S, Meikle A W. Pituitary radiographic abnormalities and clinical correlates of hypogonadism in elderly males presenting with erectile dysfunction. Aging Male 2002; 5: 38–46
   PubMedGoogle Scholar
• Rhoden E L, Estrada C, Levine L, Morgentaler A. The value of pituitary magnetic resonance imaging in men with hypogonadism. J Urol 2003; 170: 795–798
   PubMed Web of Science ®Google Scholar
• Buvat J, Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997; 158: 1764–1767
   PubMed Web of Science ®Google Scholar
• Araujo A B, O'Donnell A, Brambilla D J, Simpson W B, Longcope C, Matsumoto A M, McKinlay J B. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts male aging study. J Clin Endocrinol Metab 2004; 89: 5920–5926
   PubMed Web of Science ®Google Scholar
• Vermeulen A. Hormonal cut-offs of partial androgen deficiency: a survey of androgen assays. J Endocrinol Invest 2005; 28: 28–31
   PubMedGoogle Scholar
• Rosner W, Auchus R J, Azziz R, Sluss P M, Raff H. Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society Position Statement. J Clin Endocrinol Metab 2007; 92: 405–413
   PubMed Web of Science ®Google Scholar
• Sikaris K, McLachlan R I, Kazlauskas R, de K D, Holden C A, Handelsman D J. Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays. J Clin Endocrinol Metab 2005; 90: 5928–5936
   PubMed Web of Science ®Google Scholar
• Taieb J, Mathian B, Millot F, Patricot M C, Mathieu E, Queyrel N, Lacroix I, Somma-Delpero C, Boudou P. Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 2003; 49: 1381–1395
   PubMed Web of Science ®Google Scholar
• Wang C, Catlin D H, Demers L M, Starcevic B, Swerdloff R S. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2004; 89: 534–543
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Verdonck L, Kaufman J M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666–3672
   PubMed Web of Science ®Google Scholar
• Swerdloff R S, Wang C. Free testosterone measurement by the analog displacement direct assay: old concerns and new evidence. Clin Chem 2008; 54: 458–460
   PubMed Web of Science ®Google Scholar
• Rosner W. Errors in the measurement of plasma free testosterone. J Clin Endocrinol Metab 1997; 82: 2014–2015
   PubMed Web of Science ®Google Scholar
• Wang C, Plymate S, Nieschlag E, Paulsen C A. Salivary testosterone in men: further evidence of a direct correlation with free serum testosterone. J Clin Endocrinol Metab 1981; 53: 1021–1024
   PubMed Web of Science ®Google Scholar
• Allan C A, Strauss B J, Burger H G, Forbes E A, McLachlan R I. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 2008; 93: 139–146
   PubMed Web of Science ®Google Scholar
• Meier C, Nguyen T V, Handelsman D J, Schindler C, Kushnir M M, Rockwood A L, Meikle A W, Center J R, Eisman J A, Seibel M J. Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med 2008; 168: 47–54
   PubMed Web of Science ®Google Scholar
• Kenny A M, Prestwood K M, Raisz L G. Short-term effects of intramuscular and transdermal testosterone on bone turnover, prostate symptoms, cholesterol, and hematocrit in men over age 70 with low testosterone levels. Endocr Res 2000; 26: 153–168
   PubMed Web of Science ®Google Scholar
• Freitas S S, Barrett-Connor E, Ensrud K E, Fink H A, Bauer D C, Cawthon P M, Lambert L C, Orwoll E S. Rate and circumstances of clinical vertebral fractures in older men. Osteoporos Int 2007; 19: 615–623
   PubMed Web of Science ®Google Scholar
• Schousboe J T, Taylor B C, Fink H A, Kane R L, Cummings S R, Orwoll E S, Melton LJ I II, Bauer D C, Ensrud K E. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 2007; 298: 629–637
   PubMed Web of Science ®Google Scholar
• Morales A, Buvat J, Gorren L J, Guay A T, Kaufman J M, Tan H M, Torres L O. Endocrine aspects of sexual dysfunction in men. J Sex Med 2004; 1: 69–81
   PubMed Web of Science ®Google Scholar
• Black A M, Day A G, Morales A. The reliability of clinical and biochemical assessment in symptomatic late-onset hypogonadism: can a case be made for a 3-month therapeutic trial. BJU Int 2004; 94: 1066–1070
   PubMed Web of Science ®Google Scholar
• Shabsigh R, Kaufman J M, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004; 172: 658–663
   PubMed Web of Science ®Google Scholar
• Greenstein A, Mabjeesh N J, Sofer M, Kaver I, Matzkin H, Chen J. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed. J Urol 2005; 173: 530–532
   PubMed Web of Science ®Google Scholar
• Allen N E, Appleby P N, Davey G K, Key T J. Lifestyle and nutritional determinants of bioavailable androgens and related hormones in British men. Cancer Causes Control 2002; 13: 353–363
   PubMed Web of Science ®Google Scholar
• Kalyani R R, Dobs A S. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007; 14: 226–234
   PubMedGoogle Scholar
• Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, Nelson W G, Dobs A, Basaria S, Golden S H, Platz E A. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007; 30: 234–238
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Muller D C, Metter E J, Maggio M, Harman S M, Blackman M R, Andres R. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 2007; 92: 3568–3572
   PubMed Web of Science ®Google Scholar
• Derby C A, Zilber S, Brambilla D, Morales K H, McKinlay J B. Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) 2006; 65: 125–131
   PubMed Web of Science ®Google Scholar
• Kapoor D, Aldred H, Clark S, Channer K S, Jones T H. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007; 30: 911–917
   PubMed Web of Science ®Google Scholar
• Kupelian V, Page S T, Araujo A B, Travison T G, Bremner W J, McKinlay J B. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 91: 843–850
   PubMed Web of Science ®Google Scholar
• Laaksonen D E, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen T P, Valkonen V P, Salonen R, Salonen J T. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036–1041
   PubMed Web of Science ®Google Scholar
• Kapoor D, Goodwin E, Channer K S, Jones T H. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899–906
   PubMed Web of Science ®Google Scholar
• Corrales J J, Burgo R M, Garca-Berrocal B, Almeida M, Alberca I, Gonzalez-Buitrago J M, Orfao A, Miralles J M. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism 2004; 53: 666–672
   PubMed Web of Science ®Google Scholar
• Basu R, Dalla M C, Campioni M, Basu A, Nair K S, Jensen M D, Khosla S, Klee G, Toffolo G, Cobelli C, Rizza R A. Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. Diabetes Care 2007; 30: 1972–1978
   PubMed Web of Science ®Google Scholar
• Roddam A W, Allen N E, Appleby P, Key T J. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100: 170–183
   PubMed Web of Science ®Google Scholar
• Carpenter W R, Robinson W R, Godley P A. Getting over testosterone: postulating a fresh start for etiologic studies of prostate cancer. J Natl Cancer Inst 2008; 100: 158–159
   PubMed Web of Science ®Google Scholar
• Fowler J E, Jr, Whitmore W F, Jr. Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer. Cancer 1982; 49: 1373–1377
   PubMed Web of Science ®Google Scholar
• McConnell J D. Prostatic growth: new insights into hormonal regulation. Br J Urol 1995; 76: 5–10
   PubMedGoogle Scholar
• Parekh D J, Ankerst D P, Higgins B A, Hernandez J, Canby-Hagino E, Brand T, Troyer D A, Leach R J, Thompson I M. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology 2006; 68: 1152–1155
   PubMed Web of Science ®Google Scholar
• Thompson I M, Ankerst D P, Chi C, Goodman P J, Tangen C M, Lucia M S, Feng Z, Parnes H L, Coltman C A, Jr. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98: 529–534
   PubMed Web of Science ®Google Scholar
• Thompson I M, Carroll P R, Carducci M A. Recommendations for defining and treating high risk localized prostate cancer. J Urol 2006; 176: S6–S10
   PubMed Web of Science ®Google Scholar
• Marks L S, Mazer N A, Mostaghel E, Hess D L, Dorey F J, Epstein J I, Veltri R W, Makarov D V, Partin A W, Bostwick D G, Macairan M L, Nelson P S. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006; 296: 2351–2361
   PubMed Web of Science ®Google Scholar
• Meikle A W, Arver S, Dobs A S, Adolfsson J, Sanders S W, Middleton R G, Stephenson R A, Hoover D R, Rajaram L, Mazer N A. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology 1997; 49: 191–196
   PubMed Web of Science ®Google Scholar
• Bhasin S, Singh A B, Mac R P, Carter B, Lee M I, Cunningham G R. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003; 24: 299–311
   PubMed Web of Science ®Google Scholar
• Rhoden E L, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482–492
   PubMed Web of Science ®Google Scholar
• Agarwal P K, Oefelein M G. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005; 173: 533–536
   PubMed Web of Science ®Google Scholar
• Kaufman J M, Graydon R J. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004; 172: 920–922
   PubMed Web of Science ®Google Scholar
• Khera M, Lipshultz L I. The role of testosterone replacement therapy following radical prostatectomy. Urol Clin North Am 2007; 34: 549–553
   PubMed Web of Science ®Google Scholar
• Sarosdy M F. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007; 109: 536–541
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Behre H M. Testosterone: Action, Deficiency. Substitution. 3rd edn. Cambridge University Press, Cambridge 2004
   Google Scholar
• Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol (Oxf) 2006; 65: 275–281
   PubMed Web of Science ®Google Scholar
• Calof O M, Singh A B, Lee M L, Kenny A M, Urban R J, Tenover J L, Bhasin S. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005; 60: 1451–1457
   PubMed Web of Science ®Google Scholar
• Parsons J K, Carter H B, Platz E A, Wright E J, Landis P, Metter E J. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005; 14: 2257–2260
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 2007; 92: 3844–3853
   PubMed Web of Science ®Google Scholar
• Malkin C J, Pugh P J, West J N, van Beek E J, Jones T H, Channer K S. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 2006; 27: 57–64
   PubMed Web of Science ®Google Scholar
• Hanafy H M. Testosterone therapy and obstructive sleep apnea: is there a real connection. J Sex Med 2007; 4: 1241–1246
   PubMed Web of Science ®Google Scholar
• Drinka P J, Jochen A L, Cuisinier M, Bloom R, Rudman I, Rudman D. Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. J Am Geriatr Soc 1995; 43: 899–901
   PubMed Web of Science ®Google Scholar